Analyst Research Report Snapshot


Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review






03 May 2013





Companies referenced:


Available for Immediate Download

Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review Summary Valeant Pharmaceuticals International, Inc. (Valeant), formerly Biovail Corporation, is a specialty pharmaceutical company developing, manufacturing and marketing of a wide range of specialty, over the counter and generic pharmaceutical products. The product portfolio of the company includes specialty pharmaceuticals across various therapeutic areas; over the counter drugs; and generic pharmaceuticals. It offers dermatology, dentistry, ophthalmology, and neurology and other products. Valeant Pharmaceuticals International, Inc. Key Recent Developments: May 02, 2013: Valeant Pharma Reports Revenue Of $1.1 Billion Q1 2013 Results Feb 28, 2013: Valeant Pharma Reports Revenue Of $3.5 Billion In 2012 Jan 03, 2013: Valeant Pharma Appoints Laizer Kornwasser As Chairman Nov 02, 2012: Valeant Pharma Reports Revenue Of $884.1m In Q3 2012 Sep 13, 2012: Valeant Pharma Announces Resignation Of Rajiv De Silva As COO This comprehensive SWOT profile of Valeant Pharmaceuticals International, Inc. provides you an in-depth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description - A detailed description of the company's operations and business divisions. - Corporate strategy - Analyst's summarization of the company's business strategy. - SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats. - Company history - Progression of key events associated with the company. - Major products and services - A list of major products, services and brands of the company. - Key competitors - A list of key competitors to the company. - Key employees - A list of the key executives of the company. - Executive biographies - A brief summary of the executives' employment history. - Key operational heads - A list of personnel heading key departments/functions. - Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities - A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Note: Some sections may be missing if data is unavailable for the company. Key benefits of buying this profile include: You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors. Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the...

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.